Advanced Metastatic Solid Tumors clinical trials

Explore recruiting advanced metastatic solid tumors clinical trials.

Recruiting advanced metastatic solid tumors studies right now

Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record
Study details & eligibility ClinicalTrials.gov record

Also recruiting in Europe

Advanced Metastatic Solid Tumors trials registered in the EU Clinical Trials Information System (CTIS). These are outside the "near me" matcher above - open a study for full details.

A Phase II, Open-label, Multi-center, Basket Study of the ATR Kinase Inhibitor ART0380 Administered Orally as Monotherapy to Patients with Biologically Selected Advanced or Metastatic Solid Tumors (ARTIST)

France, Spain

Therapeutic exploratory (Phase II) EU CTIS Study details

A Phase I/IIa, Open-label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of the DNA Polymerase Theta Inhibitor ART6043 Administered Orally as Monotherapy and in Combination to Patients with Advanced or Metastatic Solid Tumors

Spain

Phase I and Phase II (Integrated)- First administration to humans EU CTIS Study details

A phase I/II trial of IOMX-0675 a fully human monoclonal antibody selectively inhibiting LILRB1/2 alone or in combination with pembrolizumab in patients with previously treated advanced/metastatic solid tumors (LIMNOS)

Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

A Phase 2 Open-Label, Multi-Center Study of BMS-986504 as Monotherapy and in Combination with Other Agents in Participants with Advanced and/or Metastatic Solid Tumors with Homozygous MTAP Deletion

Belgium, Ireland, Germany, Norway, Italy, France +1 more

Therapeutic exploratory (Phase II) EU CTIS Study details

A study to assess safety and efficacy of SOT201 in patients with advance/metastatic cancer

Belgium, Czechia, Spain

Human Pharmacology (Phase I)- First administration to humans EU CTIS Study details

REJOICE-PanTumor01: A Phase 2, Multicenter, Open-Label, Pan-Tumor Trial to Evaluate Efficacy and Safety of Raludotatug Deruxtecan (R-DXd) in Participants with Advanced/Metastatic Solid Tumors

Italy, France, Belgium, Spain, Denmark

Therapeutic exploratory (Phase II) EU CTIS Study details

Advanced Metastatic Solid Tumors trials by city

Advanced Metastatic Solid Tumors in Toronto Advanced Metastatic Solid Tumors in Vancouver Advanced Metastatic Solid Tumors in Montreal Advanced Metastatic Solid Tumors in Calgary Advanced Metastatic Solid Tumors in Edmonton Advanced Metastatic Solid Tumors in Ottawa Advanced Metastatic Solid Tumors in Winnipeg Advanced Metastatic Solid Tumors in Quebec City Advanced Metastatic Solid Tumors in Hamilton Advanced Metastatic Solid Tumors in Kitchener Advanced Metastatic Solid Tumors in London Advanced Metastatic Solid Tumors in Halifax Advanced Metastatic Solid Tumors in New York Advanced Metastatic Solid Tumors in Los Angeles Advanced Metastatic Solid Tumors in Chicago Advanced Metastatic Solid Tumors in Houston

Other conditions

Obesity Type 2 diabetes Type 1 diabetes Prediabetes Weight loss Metabolic syndrome High cholesterol High triglycerides High blood pressure PCOS Hypothyroidism Thyroid disease Gout Fatty liver disease (NAFLD/NASH) Heart failure Coronary artery disease Atrial fibrillation Stroke Stroke recovery Peripheral artery disease Pulmonary hypertension Deep vein thrombosis Chronic kidney disease Diabetic kidney disease